scholarly journals Association of Age With Tumor Grade in Patients With Digestive Tumors: A Study Based on US SEER Registry

Author(s):  
Yange Zhang ◽  
Wei Li

Abstract Background: Previous studies have not demonstrated an independent association of age and tumor grade. In this study, we aimed to explore the relationship between age and tumor grade (differentiation) in patients with digestive tumors.Methods: Surveillance, Epidemiology and End Results (SEER) 18 registry database for 1973 through 2015 was retrieved for the present study. Both piecewise and non-piecewise linear regression model were utilized to examine the relationship between age and tumor grade. Results: The present study included a total of 938,145 patients with 13 types of primary malignancies of the digestive system. In non-piecewise regression analyses, older age was associated with higher tumor grades in patients with esophageal squamous cell carcinoma (P < 0.0001) and anal squamous cell carcinoma (P < 0.0001). In contrast, older age was related to lower tumor grades in patients with esophageal adenocarcinoma (P = 0.0177), gastric adenocarcinoma (P < 0.0001), pancreatic adenocarcinoma (P < 0.0001) and rectal adenocarcinoma (P < 0.0001). In piecewise regression analyses, positive associations of age and tumor grade were only observed in specific age groups in some types of tumor, e.g., anal adenocarcinoma (> 66 years), gallbladder adenocarcinoma (> 49 years), pancreatic adenocarcinoma (> 56 years), hepatocellular carcinoma (35-90 years), rectal adenocarcinoma (<59 years in White; < 52 years in Non-White) and anal squamous cell carcinoma (<51 years in White; < 58 years in Non-White). Patients with well-differentiated tumors had better long-term prognoses compared to those with poorly-differentiated tumors (all P < 0.05). Conclusion: The patterns of relationship between age and tumor grade were different in patients with different types of digestive tumor, which may be a reflection of the distinct molecular subtypes of these tumors.

Author(s):  
Asmaa Ali Hussein

Squamous cell carcinoma characterized by poor prognosis due to aggressive tumor growth and dissemination high rate of tumor cell . age ranged of patient case included in the study 40-62 years and mean age 55±99. The sex distribution male/female ratio 1:1. Male case 15 and female 15 of the present study The results of clinical forums showed in the current study was endophytic 10(33.3%) in the same time Exophytic were presented in 20 cases (76.7%). Regarding distribution of the tumors site, the preponderance of them 19 cases 73.3% were located alveolar mucosa, followed by in the tongue 11 cases(36.7%) Tumor stage was analyzed and recorded in Oral squamous cell carcinoma included cases, the preponderance of them were Stage II 11 cases 36.7% followed by stage III 10 cases 33.3% , 9 cases 30.0% were stage I. While Concerning tumor grade, majority of them 15 cases 50% had grade II moderately differentiated SCC, while 11 cases 36.7% had grade III poorly differentiated SCC and 4 cases 13.3% had grade I well differentiated SCC Positive TGF-β3 immunostaining was detected as cell with staining brown color, all tissues sections included show Positive expression based on IHC teqnique. Positive Transforming Growth Factor TGF-β3 Immuno staining was found in all case results and display that 4 samples with percentage 13.3% expressed strong positive 87.67 ± 1.45 expression , 11cases 36.7% showed 51.33 ±0.88 positive expression moderate at the same time 15 samples 50.0% showed positive weak expression.


2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Lucía Trilla-Fuertes ◽  
Angelo Gámez-Pozo ◽  
Joan Maurel ◽  
Rocio Garcia-Carbonero ◽  
Jaume Capdevila ◽  
...  

AbstractSquamous cell carcinoma is the most frequent histologic type of anal carcinoma. The standard of care since the 1970s has been a combination of 5-fluorouracil, mitomycin C, and radiotherapy. This treatment is very effective in T1/T2 tumors (achieving complete regression in 80–90% of tumors). However, in T3/T4 tumors, the 3-year relapse free survival rate is only 50%. The VITAL trial aimed to assess the efficacy and safety of panitumumab in combination with this standard treatment. In this study, 27 paraffin-embedded samples from the VITAL trial and 18 samples from patients from daily clinical practice were analyzed by whole-exome sequencing and the influence of the presence of genetic variants in the response to panitumumab was studied. Having a moderate- or high-impact genetic variant in PIK3CA seemed to be related to the response to panitumumab. Furthermore, copy number variants in FGFR3, GRB2 and JAK1 were also related to the response to panitumumab. These genetic alterations have also been studied in the cohort of patients from daily clinical practice (not treated with panitumumab) and they did not have a predictive value. Therefore, in this study, a collection of genetic alterations related to the response with panitumumab was described. These results could be useful for patient stratification in new anti-EGFR clinical trials.


2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Danielle R. L. Brogden ◽  
Christopher C. Khoo ◽  
Christos Kontovounisios ◽  
Gianluca Pellino ◽  
Irene Chong ◽  
...  

AbstractAnal Squamous Cell Carcinoma (ASCC) is a rare cancer that has a rapidly increasing incidence in areas with highly developed economies. ASCC is strongly associated with HIV and there appears to be increasing numbers of younger male persons living with HIV (PLWH) diagnosed with ASCC. This is a retrospective cohort study of HIV positive and HIV negative patients diagnosed with primary ASCC between January 2000 and January 2020 in a demographic group with high prevalence rates of HIV. One Hundred and seventy six patients were included, and clinical data was retrieved from multiple, prospective databases. A clinical subgroup was identified in this cohort of younger HIV positive males who were more likely to have had a prior diagnosis of Anal Intraepithelial Neoplasia (AIN). Gender and HIV status had no effect on staging or disease-free survival. PLWH were more likely to develop a recurrence (p < 0.000) but had a longer time to recurrence than HIV negative patients, however this was not statistically significant (46.1 months vs. 17.5 months; p = 0.077). Patients known to have a previous diagnosis of AIN were more likely to have earlier staging and local tumour excision. Five-year Disease-Free Survival was associated with tumour size and the absence of nodal or metastatic disease (p < 0.000).


Sign in / Sign up

Export Citation Format

Share Document